Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax

Although antibiotics treat bacteremia in inhalational anthrax, pathogenesis is mainly driven by bacterial exotoxins. Raxibacumab, an IgG1 monoclonal antibody, binds the protective antigen (PA) of Bacillus anthracis, thus blocking toxin effects and leading to improved survival in the rabbit and monke...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Migone, Thi-Sau, Bolmer, Sally, Zhong, John, Corey, Al, Vasconcelos, Daphne, Buccellato, Matthew, Meister, Gabriel
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2015
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4335881/
https://ncbi.nlm.nih.gov/pubmed/25487792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04606-14
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars